Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin

Publisher： Karger

E-ISSN： 2296-5262|27|6|552-556

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.6, 2004-12, pp. : 552-556

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liposomal doxorubicin in breast cancer

By Shehata M   Mukherjee A   Sharma R   Chan S  

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 557-569

Future Medicine

Access to resources Recommend Favorite

Pyridoxine as Prophylactic Therapy for Palmar-Plantar Erythrodysesthesia Associated with Administration of Pegylated Liposomal Doxorubicin (Caelyx): A Single-Center Experience

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 277-278

Karger

Access to resources Recommend Favorite

Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-08 ,pp. : 39-41

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 23-30

Karger

Access to resources Recommend Favorite

Liposomal nanomedicine for breast cancer therapy

By Paliwal Shivani Rai   Paliwal Rishi   Agrawal Govind P   Vyas Suresh P  

Nanomedicine, Vol. 6, Iss. 6, 2011-08 ,pp. : 1085-1100

Future Medicine

Access to resources Recommend Favorite